Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4848 USD | -0.84% | -0.35% | -61.52% |
Mar. 11 | BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities | CI |
Mar. 04 | Top Midday Decliners | MT |
Valuation
Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Capitalization 1 | 72.79 | 378.5 | 36.23 | 156.4 | 26.62 |
Enterprise Value (EV) 1 | 72.79 | 378.5 | 36.23 | 156.4 | 26.62 |
P/E ratio | -2.04 x | -1.14 x | -1.37 x | -2.78 x | -0.48 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | -36,214,295 x | -1,907,599 x | - | - |
FCF Yield | - | -0% | -0% | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 5,199 | 22,333 | 24,984 | 36,281 | 54,902 |
Reference price 2 | 14.00 | 16.95 | 1.450 | 4.310 | 0.4848 |
Announcement Date | 8/6/20 | 8/30/21 | 9/27/22 | 8/16/23 | - |
Income Statement Evolution (Annual data)
Fiscal Period: Giugno | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | -2.693 | -138.1 | -27.25 | -45.08 | -48.6 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -130.2 | -26.08 | -50.26 | -49.4 |
Net income 1 | - | -183.8 | -26.08 | -50.26 | -49.4 |
Net margin | - | - | - | - | - |
EPS 2 | -6.850 | -14.82 | -1.060 | -1.550 | -1.020 |
Free Cash Flow | - | -10.45 | -18.99 | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 8/6/20 | 8/30/21 | 9/27/22 | 8/16/23 | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | - | -6.665 | -5.749 | -9.292 | -8.834 | -11.49 | -13.77 | -10.98 | - | -8.781 | -12.55 | -13.49 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -5.414 | -7.041 | -8.089 | -10.42 | -15.69 | -15.04 | -9.112 | - | -8.401 | -12.88 | -13.72 |
Net income 1 | -5.541 | -5.414 | -7.041 | -8.089 | -10.42 | -15.69 | -15.04 | -9.112 | - | -8.401 | -12.88 | -13.72 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.2300 | -0.2200 | -0.2800 | -0.3300 | -0.3800 | -0.5000 | -0.4300 | -0.2300 | -0.2900 | -0.2200 | -0.2500 | -0.2600 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/10/21 | 2/8/22 | 5/11/22 | 9/27/22 | 11/4/22 | 2/10/23 | 5/12/23 | 8/16/23 | 11/8/23 | 2/13/24 | - | - |
Balance Sheet Analysis
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | -10.5 | -19 | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 8/30/21 | 9/27/22 | 8/16/23 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.52% | 26.62M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BIVI Stock
- Financials BioVie Inc.